ProfileGDS5678 / 1423626_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 87% 86% 87% 87% 85% 86% 89% 88% 88% 89% 87% 87% 86% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.7017887
GSM967853U87-EV human glioblastoma xenograft - Control 26.5176886
GSM967854U87-EV human glioblastoma xenograft - Control 36.7096487
GSM967855U87-EV human glioblastoma xenograft - Control 46.9078987
GSM967856U87-EV human glioblastoma xenograft - Control 56.4357285
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.3345886
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.8335589
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.8142788
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.7554388
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.1075189
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.6626587
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.793187
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.5247986
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.404185